NeuroMetrix (NASDAQ:NURO) Stock Passes Above 200 Day Moving Average – Should You Sell?

NeuroMetrix, Inc. (NASDAQ:NURO) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.11 and traded as high as $4.39. NeuroMetrix shares last traded at $4.42, with a volume of 1,085 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on NeuroMetrix in a report on Thursday. They issued a “sell” rating for the company.

NeuroMetrix Trading Down 1.5 %

The stock has a market cap of $9.26 million, a P/E ratio of -0.98 and a beta of 2.15. The firm has a 50-day simple moving average of $4.29 and a two-hundred day simple moving average of $4.11.

Institutional Trading of NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.